Health impact assessment of folate biofortified rice in China by De Steur, Hans et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Department of Agricultural Economics, Division Agro-Food marketing,  
Ghent University, Belgium 
2 Unit Plant Hormone Signalling and Bio-imaging, Department of Physiology, 
Ghent University, Belgium 
3 Rural Economy Research Institute, Liaoning Academy of Agricultural 
Sciences, Liaoning, P.R. China 
4 Laboratory of Toxicology, Department of Bioanalysis, Ghent University, 
Belgium  
Hans De Steur1*, Xavier Gellynck1, Sergei Storozhenko2, Ge Liqun3, 
Willy Lambert4, Dominique Van Der Straeten2 and Jacques Viaene1  
 
Health impact assessment of folate biofortified rice in China. 
 
hans.desteur@ugent.be  
2010 
Copyright 2010 by De Steur, Gellynck, Storozhenko, Liqun, Lambert, Van Der Straeten and 
Viaene. All rights reserved. Readers may make verbatim copies of this document for non-
commercial purposes by any means, provided that this copyright notice appears on all such 
copies. 
Selected Paper  
prepared for presentation at the 1
st
 Joint EAAE/AAEA Seminar  
 
 “The Economics of Food, Food Choice and Health” 
Freising, Germany, September 15 – 17, 2010 
  
2 
Abstract       
 
Introduction: As folate deficiency is mainly caused by the dependency on folate-poor staple crops, such as rice, 
the implementation of rice with a high level of natural folate could be a successful pro-rural and pro-poor intervention 
strategy to reduce folate deficiencies in China, where about 260 million people are considered to be folate deficient. 
Consuming folate biofortified rice instead of conventional rice could prevent someone from negative health outcomes 
of folate deficiency, such as megaloblastic aneamia and neural-tube defects. Especially for poor Chinese women of 
childbearing age, folate biofortification could be important to prevent them from having a baby with a neural-tube 
defect, the main adverse health outcome. As Northern and Southern China differ significantly in terms of rice 
consumption and production, and folate intake, a regional comparison of the potential health benefits of folate 
biofortified rice could further underpin the introduction of this strategy in China.   
Objective: The aim is to measure the potential regional health impact of folate biofortified rice (12 µg per 1 
gram of rice) in China. 
Method: Based on the Disability-Adjusted Life Years (DALY) approach, the health impact of folate enriched 
rice in China is evaluated as the numbers of DALYs lost that can be reduced. As there is only data available on 
contribution of folate deficiency to its main adverse health outcome of folate deficiency, i.e. neural-tube defects, the 
health impact refers to the neural-tube defects that are caused by folate deficiency. Furthermore, two coverage rate of 
the introduction of folate enriched rice are included based on previous research. 
Results: Based on the efficacy of folate biofortified rice, the total daily folate intake for Chinese women of 
childbearing age after biofortification amounts to 1 120 µg, which is significantly higher than the required folate intake. 
The application of the DALY method shows that the implementation of folate biofortified rice could save 116 090 
DALYs (low impact scenario) and 257 345 DALYs (high impact scenario) per year. Although rice consumption is 
significantly lower in Northern China, the folate intake after biofortication is still high enough to alleviate the burden of 
neural-tube defects caused by folate deficiency. Furthermore, a rough estimation of the costs of folate biofortification 
indicates that this policy intervention could be a cost-effective method as well. 
Conclusions: Although these results underpin folate biofortification of rice as a valuable policy intervention to 
tackle folate deficiency in different regions of China, further research is required to compare the benefits and costs with 
other interventions or folate biofortified products. 
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1. Introduction 
 
Folate deficiency is an important type of micronutrient malnutrition characterized by a low intake of 
folates (< 400 µg per day). Suboptimal folate intake leads to an increased risk of several diseases, 
like neural-tube defects (NTD), megaloblastic anaemia and aggravation of iron deficiency anaemia. 
(Molloy & Scott, 2001). Folate is a water-soluble vitamin (Vitamin B9) and is available in different 
kinds of foods, such as beans and strawberries. Recently, folate biofortified rice with a high natural 
folate content was developed by Storozhenko et al. (2007). This type of folate biofortification, i.e. 
the enhancement of the natural folate content of a staple crop, can be considered as an alternative 
strategy to increase folate intake levels. Especially in regions where folic acid fortification, i.e. 
increasing the synthetic folate content of staple crops, folic acid supplementation, i.e. distributing 
folic acid pills, or food diversification, i.e. increasing the intake of folate-rich food products, are less 
successful or practically less feasible, folate biofortification could offer a solution.  
With 258.8 million or 19.6 % of the Chinese population being folate deficient, China is an 
interesting region to analyze the health impact of folate biofortified rice as a policy intervention to 
tackle folate deficiency (De Steur et al., 2010a). As a consequence, the prevalence of neural-tube 
defects, i.e. the most important health outcome of folate deficiency, in China is among the highest 
in the world. Especially Shanxi Province, where each year 60 NTDs per 10,000 births are born, 
folate deficiency is a major health problem (Dai et al., 2002; Gu et al., 2007; Li, Ren, Zhang, Guo, 
& Li, 2006). Furthermore, China is a key player in the production and consumption of rice and 
genetically modified rice (Jia, Jayaraman, & Louët, 2004; Wang & Johnston, 2007). The recently 
granted bio-safety certificates of biotech Bt rice and phytase maize by the Chinese Ministry of 
Agriculture (MOA) support this statement (Shuping & Miles, 2009). 
In this paper the health benefits of a folate biofortified product are quantified, based on the 
Disability-Adjusted Life Years (DALY) framework (Murray & Lopez, 1996; Stein, Meenakshi, 
Quinlivan, Nestel, Sachdev, & Bhutta, 2005). Because of the regional differences in rice 
consumption and folate status between the northern and southern regions, the health impact is 
analyzed at regional (administrative regions) level. Folate biofortification is not yet available on the 
market, by which this study is considered as an ex-ante evaluation of the introduction of folate 
biofortified rice. While previous health impact studies measured the impact of different biofortified 
crops, such as Golden Rice (Stein, Sachdev, & Qaim, 2006; Zimmermann & Qaim, 2004), on the 
prevalence of main micronutrient deficiencies (e.g. vitamin A deficiency), the focus here lies on 
folate biofortified rice as a policy intervention to reduce folate deficiency.  
  
4 
As a recent study analyzed the health impact of folate biofortified rice in China (De Steur et al., 
2010a), this paper builds further on their findings and includes the calculation of the potential costs 
and the cost-effectiveness.  
First, the current burden of folate deficiency in China is calculated in terms of “healthy” life years 
(DALYs lost) that are lost due to the disease. The health impact focuses on one particular health 
outcome of folate deficiency, neural-tube defects, as it is the only outcome which has a clear 
contribution level of folate deficiency. Periconceptional folate intake reduces the risk of having a 
baby with an NTD, i.e. the most common congenital malformation in the world (Lumley, Watson, 
Watson, & Bower, 2001; MRC Vitamin Study Research Group, 1991; Pinar, Tatevosyants, & 
Singer, 1998; Stockley & Lund, 2008). Second, the potential impact of the introduction of folate 
biofortification in China on this burden is measured by comparing the number of DALYs lost 
before and after folate biofortification. Third, the costs of this introduction are briefly discussed to 
come up with a rudimentary analysis of the potential cost-effectiveness of folate biofortification in 
China.  
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2. The current burden of folate deficiency in China (DALYs lost) 
 
The DALY formula 
 
The Disability-Adjusted Life Years approach quantifies the burden of a disease, e.g. folate 
deficiency as the number of DALYs lost. The number is a combination of the “Years Lived with 
Disability” (YLD) and “Years of Life Lost” (YLL), which represent, respectively, disability-
weighted morbidity and cause-specific mortality due to folate deficiency. The DALY formula 
(Stein et al., 2005; Zimmermann et al., 2004) is  expressed as:  
  
 
The input parameters of the formula are:  
- the total number of people in target group j (Tj) 
- the mortality rate associated with the deficiency in target group j (Mj) 
- the incidence rate of functional outcome i in target group j (Iij) 
- the disability weight for functional outcome i in target group j, (Dij) 
- the duration of functional outcome i in target group j (dij) 
- the average remaining life expectancy for target group j (Lj), and  
- the discount rate for future life years (r) 
 
Because there is only data available on the contribution of folate deficiency to NTDs as an adverse 
health outcome, the three main NTD types (i.e. spina bifida, anencephaly and encephalocele) 
determine the current burden of folate deficiency. Thus, only the NTDs that are attributable to folate 
deficiency are included as functional outcomes. These outcomes refer to fatal (e.g. abortions or 
stillbirths) and non-fatal NTD-births (live births suffering from spina bifida or encephalocele 
(Access Economics, 2006; Mathers, Vos, & Stevenson, 1999). The sections below describe the 
calculation method and the value(s) of the different input parameters. 
 
Input parameters of the DALY formula: Neural-tube defects caused by folate deficiency in China 
 
To calculate the number of NTDs caused by folate deficiency in China, the total number of (all) 
NTDs is measured, based on demographic and NTD-related statistics in China and its regions 
(Northeast, Northwest, Southeast and Southwest). Table 1 gives an overview of these data.  
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In 2007, about 14 million babies were born in China. The most recent life expectancy of these 
Chinese births is 71.24 years in 2000 (National Bureau of Statistics of China, 2008). The regional 
life expectancies at birth refer to the average remaining life expectancy (Lj) of stillbirths and 
abortions, one of the input parameters of the DALY formula. 
Application of the regional NTD prevalence rates (Dai et al., 2002) to the regional number of births 
results in the total number of NTDs in China (see Table 1). The share of the different functional 
outcomes is based on the composition of NTDs in the Chinese study of Li et al. (2006), where 31 % 
of all NTDs are abortions, and for 40.09 % and 28.91 % of all NTDs are considered as live births 
and stillbirths, respectively. Similar findings are found in other Chinese NTD studies (Moore et al., 
1997; U.S. Department of Health and Human Services & Centers for Disease Control, 1989). The 
composition of the two non-fatal categories is based on the Chinese study of Dai et al. (2002). The 
total annual number of NTDs in China, i.e. NTDs caused by folate deficiency or other factors, such 
as genetic or environmental causes (Sever, 1995), accounts 18 020, of which nearly 60 % is 
assumed to be fatal. The number of NTDs in Northern China is significantly higher than in its 
Southern counterpart. Almost 70 % of NTDs in China occur in one of the Northern regions.  
It is important to notice that the current burden of folate deficiency includes only the NTDs that are 
caused by folate deficiency, instead of taking all NTDs into account. Therefore, the contribution 
level of folate deficiency to NTDs has to be defined.  
There is scientific evidence on the relationship between folate deficiency and neural-tube defects, 
its main adverse health outcome. Several authors explored the effect of achieving the recommended 
folate intake on the risk of delivering a baby with an NTD (Daly et al., 1997; De Wals et al., 2007; 
Lumley et al., 2001; Molloy et al., 2001; MRC Vitamin Study Research Group, 1991). As a 
consequence, the WHO (2006) defined a daily dose of 400 µg of folates per women of childbearing 
age as the minimum folate level required for the prevention of a neural-tube defect. An intake 
below this level is considered as folate deficiency.  
In a Chinese study, Berry et al. (1999) found that if women achieve the daily folate 
recommendation of 400 µg, the number of NTDs can be reduced by 40 % and 85 % in Southern and 
Northern China, respectively. Thus, 40 % and 85% are considered as the contribution levels of 
folate deficiency (<400 µg) to NTDs in southern and northern regions, respectively. By applying 
these contribution levels to the total number of NTDs, the number of NTDs caused by folate 
deficiency can be measured for each region. Due to the high contribution level in Northern China, 
its number of NTDs attributable to folate deficiency is significantly higher than in Southern China. 
Especially in Northwest China the burden of folate related NTDs is high.  
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With respect to the different functional outcomes, spina bifida is the most common outcome of 
NTD live births, while abortions occur slightly more than stillbirths when the NTD results in a fatal 
outcome.  
The non-fatal and fatal outcomes of NTDs caused by folate deficiency are considered as the 
combined input parameters TjIij and TjMj of the DALY formula, respectively. 
 
Table 1 Demographic statistics of China, total population and births, life expectancy at birth, and neural-tube 
defects in China (all versus caused by folate deficiency) per functional outcome, per region 
 
  North   South  
China 
 Northeast Northwest Total Southeast Southwest Total 
Births
a
 4 761 446 1 267 500 6 028 946 6 524 892 2 216 919 8 741 811 14 770 757 
Life expectancy
b
 73.59 72.39 73.19 69.96 68.23 69.42 71.24 
NTD prevalence rate 19.2 22.2 19.9 5.6 6.6 5.8 12.9 
NTDs
c 
 
Non-Fatal 3 791 1 197 4 988 1 664 572 2 236 7 224 
Spina bifida 3 057 900 3 957 1 176 409 1 584 5 541 
Encephalocele 734 298 1 031 488 163 651 1 683 
Fatal  5 666 1 789 7 454 2 486 855 3 341 10 796 
Abortions 2 932 926 3 857 1 287 442 1 729 5 586 
Stillbirths  2 734 863 3 597 1 200 413 1 612 5 210 
All NTDs 9 457 2 986 12 443 4 150 1 427 5 577 18 020 
NTDs 
caused by 
folate 
deficiency 
d 
 
Non-Fatal 3 223 1 018 4 240 666 229 894 5 134 
Spina bifida 2 599 765 3 363 470 163 634 3 997 
Encephalocele 624 253 877 195 65 261 1 137 
Fatal  4 816 1 521 6 336 995 342 1 337 7 673 
Abortions 2 492 787 3 279 515 177 692 3 970 
Stillbirths  2 324 734 3 058 480 165 645 3 703 
All NTDs < folate 
deficiency  
8 038 2 538 10 576 1 660 571 2 231 12 807 
 
a Based on birth rates in 2007 (in the China Statistical Yearbook 2008 (National Bureau of Statistics of China, 2008) and population figures of 2007, 
in the China Statistical Yearbook 2008 (National Bureau of Statistics of China, 2008) 
b Regional life expectancy at birth in 2000, in the China Statistical Yearbook 2008 (National Bureau of Statistics of China, 2008) 
c Based on regional NTD prevalence rates between 1996 – 2000, in Dai et al (2002).  
d Based on the total number of NTDs and the contribution level of folate deficiency to NTDs in Northern (85 %) and Southern China (40 %). 
 
Other input parameters of the DALY formula 
 
Besides the number of fatal and non-fatal NTDs caused by folate deficiency, the DALY formula 
requires additional input parameters. The disability weights of the functional outcomes (Dij) of these 
NTDs refer to the level of disability, with a range between health (D=0) and death (D=1) (Murray et 
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al., 1996). While the disability weight of abortions and stillbirths, including anencephaly as a fatal 
NTD type, is 1, spina bifida and encephalocele have a disability weight of 0.593 and 0.520, 
respectively (1999). The duration (dij) of the latter two types are assumed to be permanent, by 
which dij equals the remaining life expectancy (Lj) or the life expectancy at birth (see Table 1). In 
accordance with previous applications of the DALY method (Stein et al., 2005; Zimmermann et al., 
2004), the discount rate for future life years (r) is 3 percent. 
 
The current burden of folate deficiency in China (DALYs lost) 
 
The current burden of folate deficiency in China and its main regions, i.e. number of DALYs lost 
per year due to the prevalence of NTDs caused by folate deficiency, can be measured by entering 
the input parameters into the DALY formula. If the current rice consumption patterns are 
maintained and folate biofortification is not implemented, the annual loss of folate deficiency in 
China amounts to 314,180 DALYs, of which 72 % and 28 % are attributable to fatal and non fatal 
outcomes, respectively. Due to a different NTD prevalence rate and a different contribution level of 
folate deficiency to NTDs, there is a higher burden of disease in Northern China and, in particular, 
in its northeast part. Most of the non-fatal DALYs are lost due to malformations of the back, also 
known as spina bifida.  
 
Table 2 The current burden of folate deficiency in China (DALYs lost per year), per functional outcome, per 
region  
  North   South  
China 
 Northeast Northwest Total Southeast Southwest Total 
Non-Fatal (YLD) 55 242 17 327 72 569 11 137 3 794 14 931 87 500 
Spina bifida 45 642 13 425 59 067 8 169 2 809 10 978 70 044 
Encephalocele 9 600 3 902 13 502 2 968 985 3 954 17 456 
Fatal  (YLL) 142 608 45 046 187 654 29 115 9 911 39 026 226 680 
Abortions 73 791 23 309 97 100 15 066 5 128 20 194 117 294 
Stillbirths  68 816 21 737 90 554 14 050 4 783 18 832 109 386 
Total  197 849 62 374 260 223 40 252 13 705 53 957 314 180 
YLD, years lived in disability; YLL, years of life lost 
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4. The health impact of folate biofortified rice in China (DALYs saved) 
 
Data and assumptions 
 
Figure 1 presents the framework to measure the health benefits of folate biofortified rice in China, 
by means of the DALY approach. To be able to calculate this health impact, additional data on the 
characteristics of folate biofortified rice (efficacy) and market characteristics (coverage, current rice 
consumption and current folate intake) are needed. The calculation method of these different 
determinants is described below. In cases were data is not available, additional assumptions had to 
be made.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Health impact assessment of folate biofortified rice as a means to tackle folate deficiency. Application of 
the DALY method (based on Zimmerman & Qaim, 2004).  
 
The efficacy of folate biofortified rice (product characteristics) determines the additional folate that 
will be consumed. It consists of three determinants: the (additional) folate content of folate 
biofortified rice, the folate losses after processing rice and the bioavailability of natural folate. 
With respect to the folate content of folate biofortified rice, different transgenic lines were obtained 
by Storozhenko et al. (2007). Compared to the initial folate content of rice, 0.08 µg per g of raw 
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polished grains, the transgenic lines are 20 to 100 times higher (US Department of Agriculture 
Agricultural Research Service, 2009). Instead of selecting one of the outliers, we decided to use 12 
µg per g raw polished grains as the folate content of folate biofortified rice. However, due to 
cooking the rice (Storozhenko et al., 2007) and the bioavailibity of natural folate, 50 % (Bailey, 
2004; FSAI, 2006), only 25 % of folate in the biofortified rice will be absorbed by the human body. 
This results in a total folate content of folate biofortified rice of 3 µg per g rice or an additional 
folate content of 2.92 µg per g when taking into account the initial folate content of rice. 
 
The total folate intake after folate biofortification is further determined by the current rice 
consumption patterns and folate intake levels in China (see Table 3). In comparison with Northern 
China, rice consumption in Southern China is more than two times larger, with the highest rice 
consumption in the southeast (435 g per day per person) (CNGOIC, 2009a). Also the current folate 
intake of women of childbearing age is significantly higher in Southern China (213 µg per day) than 
in its northern counterpart (188 µg per day). Based on these current rice consumption patterns and 
folate intake levels, the regional folate intake of women of childbearing age after folate 
biofortification varies between 638 µg per day in Northwest China and 1 487 µg per day in 
Southeast China. The folate intake level after the introduction of folate biofortification exceeds the 
recommended nutrient intake level of folates.  
 
Table 3 Current rice consumption and folate intake before/after folate biofortification in China, and % of RNI, 
per region 
   North   South  
China 
  Northeast Northwest Total Southeast Southwest Total 
Rice consumption
a
 g /day/person 186.5 156.1 181.1 435.5 348.8 412.9 315.3 
Folate intake         
Before 
µg /day/CBAb 190.9 182.7 188.0 215.1 210.4 212.9 199.8 
% of RNIc 47.7 45.7 47.0 53.8 52.6 53.2 49.9 
After 
µg /day/CBA 735.4 638.4 716.9 1 486.8 1 228.9 1 418.6 1 120.4 
% of RNIc 183.9 159.6 179.2 371.7 307.2 354.6 280.1 
 
RNI, the recommended nutrient intake; CBA, woman of childbearing age 
a The daily rice consumption per person is based on data from China’s National Grain and Oils Information Center per person, in 2007 (CNGOIC, 
2009b),  
b The current, regional folate intake levels are based on to a study of Zhao et al(2009). 
c Comparison of the total folate intake before/after biofortification with the recommended nutrient intake (RNI) of folate: 400 µg per day.  
 
The coverage rate defines the market potential of folate enriched rice and refers to the acceptance of 
women and the accessibility to farmers in favor of folate biofortified rice.  
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A low and high coverage rate are defined, based on the acceptance rates of folate biofortified rice 
from a recent study in the Chinese Shanxi Province (De Steur et al., 2010b). The authors found that 
55.4 % of all female rice consumers are willing to accept it, while 32.3 % react indifferent and 12.3 
% are reluctant. The acceptance rate of farmers is 66.7 %, with 26.7 % of the farmers being 
indifferent. The low (36.95 %) coverage rate consists of female consumers in favor of folate 
biofortified rice, which have access to enthusiastic farmers. The high coverage rate (81.91 %) 
includes both females and farmers that are favorable of or indifferent to folate biofortified rice. By 
doing so, the coverage rate defines a market of women that can and will switch completely to folate 
biofortified rice.  
Finally, the health impact of these folate intake levels after the introduction of folate biofortification 
(see Table 3) should be defined. Due to a lack of scientific evidence on the health effect of an 
increased folate intake, the dose-response function refers to the required folate intake level to 
prevent the risk of having a baby with an NTD, a daily folate intake of 400 µg. Therefore, folate 
intake levels above this threshold are assumed to result in the prevention of folate deficiency and its 
adverse health outcomes, such as neural-tube defects. Table three shows that all regional folate 
intake levels after biofortification exceeded the threshold of folate deficiency. In Southern China, 
for instance, the folate intake level after implementing the folate biofortified rice is 355 % of the 
required folate intake. In Northern China, the folate intake level is significantly lower than in 
Southern China, but still high enough to prevent women from having a baby with an NTD caused 
by folate deficiency.  
Thus, introducing folate enriched rice with a folate content of approximately 12 µg per g rice 
prevents maternal folate deficiency and the risk of having a baby affected with an NTD caused by 
folate deficiency.  
 
Health impact assessment of introducing folate biofortified rice in China (DALYs saved) 
 
Due to the efficacy of folate enriched rice and the dose-response relationship, the introduction of 
folate biofortified rice in China is expected to lower the current burden of folate deficiency. Based 
on the low (36.95 %) and high (81.91 %) coverage rate of folate biofortified rice, the health impact 
of its introduction can be measured in terms of DALYs saved, which is:  
 
Health impact = DALYs saved = DALYs lost (current burden of folate deficiency) – DALYs lost 
(reduced burden of folate deficiency) 
The results are expressed as the number of DALYs saved through the implementation of folate 
enriched rice (see Table 4). 
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These scenarios start from the assumption that the total folate intake under biofortification in each 
administrative area in China is significantly higher than the threshold to prevent folate deficiency 
and the risk of delivering a baby affected with an NTD (see Table 6). 
Each year, respectively 116 090 DALYs and 257 345 DALYs can be saved in the low and high 
impact scenario. In comparison with non-fatal outcomes of NTDs, the fatal outcomes gain more or 
less twice the number of DALYs.  After biofortification, about 200 000 and 57 000 DALYs are still 
lost each year, due to folate deficiency (and its relationship with NTDs). While the lowest number 
of saved DALYs obtained in Southwest China, the benefits are the highest in Northeast China. 
 
Table 4 Health impact assessment of folate biofortified rice in China, low and high impact scenario (DALYs 
saved per year, per functional outcome), per region  
 
   North   South  
China 
  Northeast Northwest Total Southeast Southwest Total 
L
o
w
 i
m
p
a
ct
a
 
Non-Fatal (YLD) 20 412 6 402 26 814 4,115 1 402 5 517 32 331 
Spina bifida 16 865 4 960 21 825 3 018 1 038 4 056 25 881 
Encephalocele 3 547 1 442 4 989 1 097 364 1 461 6 450 
Fatal  (YLL) 52 694 16 645 69 338 10 758 3 662 14 420 83 758 
Abortions 27 266 8 613 35 879 5 567 1 895 7 462 43 340 
Stillbirths  25 428 8 032 33 460 5 191 1 767 6 959 40 418 
Total  73 105 23 047 96 152 14 873 5 064 19 937 116 090 
H
ig
h
 i
m
p
a
ct
b
 
Non-Fatal (YLD) 45 248 14 193 59 441 9 122 3 108 12 230 71 671 
Spina bifida 37 385 10 996 48 382 6 691 2 301 8 992 57 373 
Encephalocele 7 863 3 197 11 060 2 431 807 3 238 14 298 
Fatal  (YLL) 116 810 36 897 153 707 23 848 8 118 31 966 185 674 
Abortions 60 442 19 092 79 535 12 340 4 201 16 541 96 076 
Stillbirths  56 367 17 805 74 173 11 508 3 917 15 426 89 598 
Total  162 058 51 090 213 149 32 971 11 226 44 197 257 345 
YLD, years lived in disability; YLL, years of life lost 
a Based on a low coverage rate, i.e. 36.95 %.  
b Based on a high coverage rate, i.e. 81.91 %.  
 
Table 5 presents the relative health impact of folate biofortification in China, i.e. population 
weighted DALYs. These results show that the burden and health impact are relatively lower in 
Northern China, especially in the northwest. Although the absolute burden of folate deficiency is 
higher in the northeast, relatively more DALYs lost in Northwest China.  
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Table 5 Absolute and relative (DALYs per 10 000 persons) health impact assessment of folate biofortified rice in 
China, current burden, low and high impact scenario, per region  
 
  North   South  
China 
 Northeast Northwest Total Southeast Southwest Total 
DALYs lost (current)        
Absolute  197 849 62 374 260 223 40 252 13 705 53 957 314 180 
Relative  4.31 6.39 4.68 0.71 0.69 0.71 2.38 
DALYs saved (low)
a
         
Absolute  73 105 23 047 96 152 14 873 5 064 19 937 116 090 
Relative  1.59 2.36 1.73 0.26 0.25 0.26 0.88 
DALYs saved (high)
b
        
Absolute 162 058 51 090 213 149 32 971 11 226 44 197 257 345 
Relative 3.53 5.23 3.83 0.58 0.56 0.58 1.95 
a Based on a low coverage rate, i.e. 36.95 %.  
b Based on a high coverage rate, i.e. 81.91 %.  
 
5. Cost-effectiveness of folate biofortified rice 
 
Building upon the investigated health impact, the cost-effectiveness of the introduction of folate 
biofortified rice in China can be assessed. This can be done by juxtaposing the costs of 
biofortification, research and social marketing costs, and the calculated health benefits. The time 
frame used in this study is 30 years, which is in correspondence with previous health impact studies, 
such as Stein et al. (2007; 2008). Table 6 gives an overview of the first rudimentary cost calculation 
of the introduction of folate biofortification in China. It is important to notice that the results are 
only an indication of the potential cost-effectiveness of folate biofortification in China. These 
findings should be interpreted very carefully and need to be verified and/or adjusted by additional 
experts in the field. 
The basic and advanced R&D costs to develop folate biofortified rice are assumed to be equal in the 
two impact scenarios, respectively 4.5 and 1.5 million US$. The country-specific costs, and the 
regulatory process in particular, are important determinants of the cost-effectiveness of this policy 
intervention. After the release of folate biofortified rice, which is assumed to take place in 2019, 
social marketing costs need to be taken into account. As folate biofortification of rice does not alter 
the color of rice, the costs to disseminate and promote folate biofortified rice in China are assumed 
to be lower than in the case of the yellowish Golden Rice (between 15 and 30 million US$, see 
Stein et al., 2008). Nevertheless, as a consumer survey in Shanxi Province shows, it will be an 
important challenge to reach the high-risk groups, such as poor, low educated women from rural 
regions, as these are the ones that are least willing to accept folate biofortified rice (De Steur et al., 
  
14 
2010b). The first maintenance breeding costs will be made in the year of the release and amount to 
a total of 2 million US$. 
As the coverage rate probably will not be reached in the first years of the implementation of folate 
biofortified rice in China, a growing share of the coverage rates is included in the time frame. It is 
assumed that after the release of folate biofortified rice, it will take about 8 years to reach the 
coverage rate, the maximum spread of folate enriched rice, based on its acceptance and 
accessibility. The coverage rates depend on the rice variety that has been selected. Crossing the 
folate trait with rice with successful agronomic traits, such as Bt Rice, is assumed to have a positive 
influence on the market share of folate enriched rice.  
 
Table 6 Estimation of the duration, the costs and the coverage rate of introducing folate biofortified rice in 
China, low and high impact scenario 
 Time frame  Costs (US$) Coverage rate (% reached)
 g
 
 (2002-2031)
d
 Low
e
 High
f
 Low High 
Costs      
Basic R&D
a
 2002-2010 4.5 mi. 4.5 mi. NA NA 
Advanced R&D
b
 2010-2014 1.5 mi. 1.5 mi NA NA 
Country-specific costs
c
 2014-2019 12 mi. 8 mi. NA NA 
Social marketing 2019-2031 8 mi. 15 mi. NA NA 
Maintenance breeding 2019-2031 2 mi. 2 mi. NA NA 
Coverage rate      
Phase 1 2019-2021 NA NA 25 % 25 % 
Phase 2 2022-2024 NA NA 50 % 50 % 
Phase 3 2024-2026 NA NA 75 % 75 % 
Phase 4 2027-2031 NA NA 100 % 100 % 
Total  2002-2031 28 mi. 31 mi. 36.95 % 81.91 % 
Remark: estimated release of folate enriched rice in 2019  
Source: Expert meetings with GR HUMBO and Physiology of Ghent University; Stein et al. (2008) 
NA, not applicable 
a Development of rice with a high folate content 
b Development of alternative antibiotic resistant markers instead of the antibiotic marker genes 
c Chinese R&D costs include field trials (2014-2018), backcrossing costs (elite event selection in 2016), small and large scale feeding tests (2016-
2019) and regulatory process (2016-2019) 
d The costs and benefits of the introduction of folate biofortified rice in China are projected over 30 years. 
e The costs in the low impact scenario consists of higher R&D and country-specific costs, but lower social marketing costs, which is based on the 
assumption of weak governmental support.  
f The costs in the high impact scenario consists of lower R&D and country-specific costs, but the strong political support increases the efforts, and 
thus, costs of intensive country-wide social marketing activities. 
g The percentages refer to the share of the coverage rate, the total number of women of childbearing age with a biofortified diet. As the total coverage 
rate is not reached in the first years, 4 different phases are included. Each phase refers to a specific percentage of the coverage rate and a defined 
period, starting in 2019 to 2025, where the total coverage rate is achieved. 
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Based on the health impact analysis (see Table 5) and the cost estimates (see Table 6), the cost per 
DALY saved can be assessed. This is done by comparing the Net Present Value (NPV) of the total 
costs and total DALYs saved, discounted at 3 %, similar to previous cost-effectiveness analyses of 
biofortified staple crops (Stein et al., 2007; Stein et al., 2008): 
 
 
 
The input parameters of the formula are year (t), ranging from 1 to 30, the total costs at year t (Ct), 
and the discount rate for future life years (r). The total cost per DALY saved is, respectively     
34.39 US$ and 16.34 US$ in the low and high impact scenario. Compared with the World Bank 
(1994) threshold of cost-effective micronutrient policy interventions, US$ 50 per DALY saved in 
1994, or 73.55 US$ in 2010 (BLS, 2010), the rudimentary estimate of the cost-benefit of folate 
biofortification seems to be promising.  
 
Table 7 Estimation of the cost per DALY saved, based on the Net Present Value (NPV) of the total costs and total 
DALYs, in US$, low and high impact scenario 
 Low High 
NPV costs 17.53 mi. US$ 18.46 mi US$ 
NPV DALYs 0.51 mi. DALYs 1.13 mi. DALYs  
Costs per DALY saved 34.39 US$  16.34 US$ 
 
 
6. Discussion 
 
The results of the application of the DALY method to the potential introduction of folate enriched 
rice in China are highly dependent of the quality and appropriate use of the different parameters of 
the DALY framework (see also De Steur, et al, 2010). The use of a threshold of folate deficiency 
instead of a dose-response relationship is one of the most important limitations of the study. To 
analyze the response of the folate doses in the different regions (i.e. intake levels after 
biofortification), these doses are compared with the general threshold to prevent a mother of having 
a baby with a neural-tube defect caused by folate deficiency, i.e. 400 µg of folate per day, per 
person. Nevertheless, as there is no clear non-linear relationship between folate deficiency and 
neural-tube defects, the general recommended threshold is a valuable indicator to evaluate folate 
intake levels after folate biofortification.  
Furthermore, only the main adverse health outcome of folate deficiency is included in the health 
impact analysis, i.e. neural-tube defects. Taking into account other negative health outcomes, such 
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as aneamia, would definitely increase the burden of folate deficiency, and thus, the health impact of 
folate biofortified rice. Also the input parameters of the DALY framework have an important effect 
on the number of DALYs lost and saved. Using maternal instead of general rice consumption data, 
for instance, could have an influence on the results. Other input parameters refer to different years, 
such as the life expectancy rate in 2000 and the birth rate in 2007. 
Although the health impact focuses on the reduction of neural-tube defects and, thus, newborns, it is 
important to notice that also women are directly influenced through their biofortified diet. 
Therefore, women should be the main target of social marketing to increase the coverage rate of 
folate biofortified rice. As poor, less educated women, for whom the need is greatest, are less 
willing to consume folate biofortified rice (De Steur et al., 2010b), specific groups and regions need 
to be tackled in communication programs.  
Regarding the cost-effectiveness analysis, in-depth analysis and verification of the different costs of 
the introduction of folate biofortification in China is required. Furthermore, policy issues regarding 
the price of folate enriched rice, promotion campaigns, the selected variety, and so on, needs to be 
addressed. Nevertheless, a first glance at the costs of introducing folate biofortified rice in China 
reveals that this policy intervention could be a valuable, cost-effective method to reduce folate 
deficiency and the number of neural-tube defects. Given that the burden of folate deficiency will be 
larger when all negative health outcomes of folate deficiency would be included, the cost per 
DALY saved could be even lower. 
Future research should further improve the quality of some of the input parameters of the DALY 
framework and the cost-calculation. With respect to folate deficiency, there is need for a well 
defined contribution level to each of its health outcomes. In this way, the total burden of folate 
deficiency could be measured, instead of the burden of neural-tube defects caused by folate 
deficiency. Furthermore, as our coverage rates are based on a regional consumer survey in Shanxi 
Province, the potential coverage rate of folate biofortified rice should be investigated in each region. 
To further evaluate the market potential of folate biofortified rice, it is important to compare the 
costs and benefits of different policy interventions to reduce (the impact of) folate deficiency in 
China, such as the distribution of folic acid supplementation or introducing grains fortified with 
folic acid.  
 
7. Conclusions 
 
By applying the DALY method, the potential health impact of folate biofortified rice in China is 
assessed in terms of the number of DALYs that can be saved through the biofortified diet. 
Compared with the current burden of folate deficiency, 314 180 DALYs, between 166 090 and 257 
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345 DALYs can be saved in low and high impact scenario. With respect to the Chinese regions, the 
burden and health impact are significantly lower in Southern China. Although folate deficiency 
rates are higher and rice consumption is lower in Northern China, the additional folate intake after 
biofortification of 2.92 µg per g rice is sufficient to prevent women from having a baby with a 
neural-tube defect caused by folate deficiency. The regional, average daily folate intake levels range 
between 545 µg and 1 941 µg per woman of childbearing age, which exceed the recommended 
threshold of folate deficiency (400 µg). 
Although China is a valuable region to introduce folate biofortified rice as a means to tackle folate 
deficiency, given its world leading position in rice production and consumption and its favorable 
position towards genetically modified rice, increasing the coverage rate will be one of the main 
challenges to successfully implement folate biofortification in China. Especially in poor regions 
where other folate interventions are practically not feasible, the implementation of folate 
biofortified rice could be a valuable alternative. Nevertheless, a combined intervention will be 
probably the most effective way to alleviate folate deficiency. 
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